Company
A clinical-stage biotechnology company
PEP-Therapy is a Paris-based biotechnology company developing next-generation therapies using our intracellular drug delivery shuttle.
Our technology platform enables us to address the previously undruggable intracellular space with multiple payloads such as peptides, proteins, antibodies, and nucleic acids.
As a demonstrator, PEP-010, our first drug candidate developed in oncology, is a pro-apoptotic peptide which has shown anti-tumoral activity and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and Gustave Roussy.
+ PRODUCTS
OUR MISSION
PEP-Therapy develops next-generation intracellular targeted therapies, improving drug performance with efficient cell delivery.
OUR VISION
Become a global reference in smart cell-penetrating medicines that transform patient outcomes, through strategic partnerships.
Backed by international investors
PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partners, CapHorn, i&i Prague, Business Angels des Grandes Ecoles (BAdGE), and Jérôme Majoie (former Managing Director of Laboratoires Fournier affiliates (USA, UK, Sweden, Japan), CEO of La Fondation Fournier-Majoie).
Our partners
Our partners